Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 5/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.52 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31602900 | 0.87 | RORC (0.46) | STSGPR119MEN1KMT2ATP53 | |
| SCHEMBL3813527 | 0.86 | STS (0.62) | STSGPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL27599354 | 0.85 | GPR119 (0.52) | STSGPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL5593571 | 0.85 | RAB9A (0.53) | MEN1KMT2AHPGD | |
| SCHEMBL1861675 | 0.85 | RAB9A (0.53) | MEN1KMT2AHPGD | |
| SCHEMBL15566264 | 0.85 | MEN1 (0.54) | STSGPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL13261141 | 0.85 | STS (0.52) | STSGPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL1817004 | 0.85 | MGLL (0.54) | STSGPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL13261261 | 0.85 | STS (0.54) | STSGPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL9003283 | 0.85 | STS (0.54) | STSGPR119HSD11B1PTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111513-A1 | COMPOUNDS USEFUL IN THE MODULATION OF KLHDC1 AND KLHDC2 ACTIVITY | NURIX THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| CN-119894897-A | Heteroaromatic compounds for the treatment of neurological disorders | 苏文生命科学有限公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20250084090-A1 | SUBSTITUTED LACTAMS SHOWING SEROTONIN 5-HT RECEPTOR ACTIVITY | Sumitomo Pharma Co., Ltd. (JP) | 2025-03-13 | — | — | US | disclosed |
| US-12180213-B2 | Substituted pyrazoles showing serotonin 5-HT receptor activity | SUMITOMO PHARMA CO. LTD. (JP) | 2024-12-31 | — | — | US | disclosed |
| WO-2024042480-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | SUVEN LIFE SCIENCES LIMITED (IN) | 2024-02-29 | — | — | WO | disclosed |
| US-20230008875-A1 | SUBSTITUTED LACTAMS SHOWING SEROTONIN 5-HT RECEPTOR ACTIVITY | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-12 | — | — | US | disclosed |
| US-20230008875-A1 | SUBSTITUTED LACTAMS SHOWING SEROTONIN 5-HT RECEPTOR ACTIVITY | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-12 | — | — | US | disclosed |
| US-11466007-B2 | Substituted lactams showing serotonin 5-HT receptor activity | Sumitomo Pharma Co., Ltd. (JP) | 2022-10-11 | — | — | US | disclosed |
| US-11420961-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2022-08-23 | — | — | US | disclosed |
| EP-3717477-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-07-20 | — | — | EP | disclosed |
| US-20200172543-A1 | CONDENSED LACTAM DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-06-04 | — | — | US | disclosed |
| US-20200172543-A1 | CONDENSED LACTAM DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-06-04 | — | — | US | disclosed |
| WO-2020022237-A1 | FUSED RING LACTAM DERIVATIVES | 大日本住友製薬株式会社 | 2020-01-30 | — | — | WO | disclosed |
| US-9770452-B2 | Quinoxaline derivatives as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-26 | — | — | US | disclosed |
| US-20170035775-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-9487526-B2 | Quinoxaline derivatives as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-08 | — | — | US | disclosed |
| EP-2882722-B1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | TAKEDA PHARMACEUTICAL (JP) | 2016-07-27 | — | — | EP | disclosed |
| US-20150232469-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. | 2015-08-20 | — | — | US | disclosed |
| EP-2882722-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | Envoy Therapeutics Inc. (US) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014028479-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. (US) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084090-A1 | SUBSTITUTED LACTAMS SHOWING SEROTONIN 5-HT RECEPTOR ACTIVITY | HTR1A, HTR5A, TPH1 | STS 135/4885GPR119 263/4885HSD11B1 508/4885 |
| US-20150232469-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | GPR6, GRM6, GPR65 | STS 3263/4885GPR119 25/4885HSD11B1 2943/4885 |
| US-12180213-B2 | Substituted pyrazoles showing serotonin 5-HT receptor activity | HTR5A, HTR1A, TPH1 | STS 591/4885GPR119 163/4885HSD11B1 396/4885 |
| US-11420961-B2 | Heterocyclic compounds | LPXN, MLX, CCNY | STS 679/4885GPR119 3037/4885HSD11B1 1138/4885 |
| US-20170035775-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | GPR6, GRM6, GPR65 | STS 3263/4885GPR119 25/4885HSD11B1 2943/4885 |
| US-11466007-B2 | Substituted lactams showing serotonin 5-HT receptor activity | HTR1A, HTR5A, TPH1 | STS 135/4885GPR119 263/4885HSD11B1 508/4885 |
| US-20230008875-A1 | SUBSTITUTED LACTAMS SHOWING SEROTONIN 5-HT RECEPTOR ACTIVITY | HTR1A, HTR5A, TPH1 | STS 135/4885GPR119 263/4885HSD11B1 508/4885 |
| US-20200172543-A1 | CONDENSED LACTAM DERIVATIVE | PSEN1, GRIN1, HDAC1 | STS 142/4885GPR119 3127/4885HSD11B1 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.